Semaglutide may help reduce heart failure and death

Embargoed until: Publicly released: 2024-08-30 17:48

Australia; International; NSW; VIC; ACT

CC0 Unplash

Semaglutide, the diabetes drug that has now become best known for its weight loss properties, can reduce the risk of heart failure events and cardiovascular death in people with diabetes, and chronic kidney disease, according to international and Australian research. The study, which was an analysis of data from a previous clinical trial called the FLOW trial, found that semaglutide could reduce the risk of heart failure events by 27%, and reduce the risk of death by 29%. A second study in the same journal found that semaglutide can also improve some of the changes to heart structure that occur with obesity and which can lead to heart failure. The Australian and international authors say this points to how the drug may be working to benefit people with obesity-related heart failure.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research American College of Cardiology, Web page Paper 1 - Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Research American College of Cardiology, Web page Paper 2 - Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Editorial / Opinion American College of Cardiology, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Journal/
conference: Journal of the American College of Cardiology

Research:Paper

Organisation/s: The University of New South Wales, The University of Melbourne, The Australian National University, AdventHealth Translational Research Institute, USA, Harvard Medical School, USA

Funder: The FLOW trial was funded by Novo Nordisk A/S. The STEP-HFpEF and STEP-HFpEF DM trials were sponsored by Novo Nordisk A/S. See papers for extensive conflict of interest statements

Media Contact/s

Contact details are only visible to registered journalists.